Novo Nordisk Launches Affordable Oral Wegovy Pill in US, Pricing Starter Doses at $149 Per Month for Self-Pay Patients

Spread the Message

Read Time:4 Minute, 38 Second

Novo Nordisk announced on January 5, 2026, the nationwide launch of its Wegovy pill, the first FDA-approved oral GLP-1 receptor agonist for chronic weight management in adults with obesity or overweight with weight-related conditions. The once-daily semaglutide tablet offers self-pay patients starter doses at $149 per month, a fraction of the injectable version’s typical $1,000 monthly list price, potentially broadening access amid soaring obesity rates affecting over 40% of US adults. This development follows FDA approval in late December 2025 and aligns with efforts by President Donald Trump to lower obesity drug costs through deals with manufacturers.

Key Developments and Pricing Details

The Wegovy pill, containing the active ingredient semaglutide, matches the efficacy of its injectable counterpart but eliminates needles, appealing to patients averse to injections. Self-pay pricing starts at $149 monthly for the 1.5 mg starter dose and 4 mg dose (until April 15, 2026, then $199 for 4 mg), with higher 9 mg and 25 mg doses at $299 per month—far below the $349 cash price for Wegovy injections introduced in November 2025. Commercially insured patients may pay as little as $25 monthly via NovoCare savings offers, and the pill is available at pharmacies like CVS and Costco, plus telehealth platforms including Ro and GoodRx.

This pricing strategy stems partly from a White House agreement under President Trump, mandating $149 starter doses for Medicare, Medicaid, and cash payers via the upcoming TrumpRx site. Novo positions the pill as a convenient option for sustained weight loss when paired with diet and exercise, targeting the 307 adults studied in the pivotal OASIS 4 phase 3 trial.

Clinical Evidence from OASIS 4 Trial

FDA approval hinged on the OASIS 4 trial, a 64-week, randomized, double-blind study of 307 adults with obesity or overweight (without diabetes) and comorbidities. Participants on 25 mg oral semaglutide once daily, plus reduced-calorie diet and exercise, achieved 13.6% average weight loss (treatment-policy estimate) versus 2.4% on placebo; full-adherence analysis showed 16.6% loss. One-third of adherent patients lost 20% or more body weight, comparable to injectable Wegovy’s results in prior STEP trials (around 15-17% loss).

Benefits extended to cardiometabolic improvements: better glycemic control (70% prediabetes normalization), blood pressure reduction, and cardiovascular risk factor enhancements. The trial confirmed a safety profile akin to injectables, with gastrointestinal events (nausea, diarrhea, vomiting) most common—mild to moderate, transient, and affecting 74% versus 42% on placebo—leading to 7% discontinuation. Serious adverse events were lower (3.9% versus 8.8%).

Longer-term injectable Wegovy data (up to four years) supports sustained loss: over 10% average at two years, with 68% achieving ≥5% loss versus 21% on placebo, and no new safety signals beyond known risks like gallstones (2.8% versus 2.3%).

Expert Perspectives

Dr. Jen Manne Goehler, an obesity specialist at Mass Brigham, notes the pill’s weight loss mirrors the injection’s, with similar gastrointestinal side effects, but requires an empty stomach and 30-minute wait before eating. “The biggest difference is convenience for needle-phobic patients,” she said in a recent interview, emphasizing total weight loss equivalence.youtube

Dr. Donna Ryan, Pennington Biomedical Research Center, led analyses affirming GLP-1s like semaglutide as viable long-term options, given over a decade of diabetes use data. However, Dr. Robert Lustig, UC San Francisco neuroendocrinologist, cautions against lifelong use, especially in youth, citing pancreatitis risks with prolonged exposure. Dr. William Yancy, Duke Lifestyle and Weight Management Center, deems it safe based on current evidence but urges ongoing monitoring.

Public Health Context and Implications

Obesity drives $173 billion in annual US medical costs, with GLP-1s like Wegovy also slashing cardiovascular events by 20% in high-risk adults per the SELECT trial (6.5% versus 8% events). Previously limited by high costs ($8,000-$16,000 yearly list) and insurance gaps—only 20% of large employers cover for weight loss—the pill could treat millions more, especially self-pay or underinsured.

For patients, this means easier adherence: swallow once daily versus weekly shots, potentially aiding the 90% who maintain ≥80% loss on continued therapy. Public health gains include reduced diabetes, heart disease incidence, but require lifestyle integration to avoid rebound (up to 14% regain off-drug). Lower prices may spur Medicare/Medicaid coverage, though budget debates persist.

Limitations, Risks, and Competition

Common side effects mirror injectables: nausea (up to 44%), diarrhea, vomiting, constipation, abdominal pain—typically dose-dependent and fading. Rarer risks include pancreatitis, gallbladder issues, hypotension, and kidney stones; long-term thyroid concerns remain monitored, though not elevated in trials. Weight regain post-discontinuation underscores need for indefinite use in many, raising adherence and cost sustainability questions.

Eli Lilly’s orforglipron, an oral GLP-1 without dietary restrictions, awaits FDA decision (expected March 2026), intensifying competition. Critics highlight off-label misuse and supply strains, urging holistic approaches over “quick fixes.”

This launch democratizes access to proven therapy, but success hinges on education, monitoring, and addressing equity gaps.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.